Kornimate/medical-research-clean huggingface dataset:
community-based exercise and nutrition training and education program for cancer survivors

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial evaluates whether a supervised community-based exercise and nutrition program is usable and effective for improving cancer survivors' confidence for maintaining their physical activity and nutrition. cancer survivors often experience problems with the musculoskeletal system (bones, joints, muscles, connective tissue), the cardiopulmonary system (heart, blood vessels and lungs) and the metabolic system (how the body's cells change food into energy) following treatment. there is substantial evidence that physical activity, diet, and weight management can improve quality of life (emotional and physical well-being) and physical fitness. information gathered from this study may help researchers determine whether participating in a community-based exercise/nutrition training and education program may improve levels of fitness, cardiovascular health, and quality of life for cancer survivors.

primary objective: i. to assess the feasibility and acceptability of a 12-week supervised community-based exercise/nutrition training and education program for cancer survivors. secondary objective: i. to assess the effectiveness of a supervised exercise and nutrition training and education program by evaluating pre-post changes in exercise self-efficacy. tertiary objective: i. to assess changes in functional performance and quality of life (qol). outline: patients participate in a supervised, community-based exercise program consisting of aerobic and resistance exercise over 45-60 minutes twice a week (biw) for 12 weeks. beginning at week 2, patients also receive nutrition education and training once a week (qw) for 10 weeks. patients also wear an activity tracker throughout the study. after completion of study intervention, patients are followed up at 3 months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * have had a previous cancer diagnosis and completed all therapy or are a caregiver for a patient who has had a previous cancer diagnosis. * participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related interventions. exclusion criteria: * have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia including atrial fibrillation (afib), multiple myeloma, or psychiatric illness/social situations that would limit compliance with study requirements. * have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise. * are pregnant or nursing. * history of a stem cell transplant. * currently on steroids. * unwilling or unable to follow protocol requirements. * any condition which in the investigator's opinion deems the participant an unsuitable candidate to participate in the study.
evaluation of ossix-plus resorbable collagen membranes for alveolar ridge preservation following exodontia

Conditions: Alveolar Bone Loss; Loss of Teeth Due to Extraction; Edentulous Alveolar Ridge

Summary: the purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets covered with a resorbable collagen membrane (ossix-plus) 12 weeks following exodontia.

reduction in alveolar ridge height and width may prohibit optimal implant placement, and often compromises the esthetic and functional result. alveolar ridge preservation has been evaluated in many studies. a variety of bone grafting materials and barrier membranes have been studied for their ability to enhance bone formation in damaged alveolar ridges, and to evaluate their bone healing and bone-forming capacity in extraction sockets. however, the newly developed resorbable collagen membrane ossix-plus has not been evaluated for this purpose. this study is designed to test the ability of ossix-plus (orapharma inc., warminster, pennsylvania) in promoting optimal bone healing following exodontia. we hypothesize that use of ossix-plus will result in preservation of the height, width and density of the residual alveolar ridge following tooth extraction.

Eligibility criteria:
inclusion criteria: * systemically healthy subjects with 1 maxillary premolar tooth requiring extraction * residual extraction sockets must have \< 80% bone loss in all dimensions (3 or 4-walled bony defects) * nonsmokers (individuals who quit smoking at least 6 months prior to the study will be allowed to participate) * subjects willing and able to comply with all study-related procedures including maintenance of good oral hygiene and compliance with re-evaluation appointments * subjects who read, understand and are willing to sign an informed consent statement exclusion criteria: * inadequate zone of keratinized gingiva (kg) or alveolar mucosa to obtain primary wound closure of the surgical site * presence of acute infections at the time of tooth extraction * clinically significant or unstable (as defined by the investigators) systemic diseases affecting bone or soft tissue growth or other renal, hepatic, cardiac, endocrine, hematological, autoimmune or acute infectious diseases that makes interpretation of the data more difficult * history of head \& neck radiation therapy * subjects taking steroids, tetracycline or tetracycline analogs, bone therapeutic levels of fluorides, biphosphonatesm, medications affecting bone turnover, antibiotics for \> 7 days or any investigational drug * patients who are or become pregnant during the length of the study * sites in which one or both adjacent teeth are missing

Keywords: extraction implant alveolar ridge preservation
mass spectrometry based cutoffs for cortisol after stimulation tests

Conditions: Adrenal Insufficiency

Summary: there are two main stimulation tests used to decide if a patient has cortisol deficiency. it is the "synacthen test", were we stimulate the patient with intramuscular or intravenous synacthen ( acth) to see how much cortisol the adrenals are capable of producing, and it is the "insulin hypoglycemia test" were we give the patient insulin to provoke a hypoglycemia, and look at the adrenal response to that stimulus. the cut off values for a normal response is based on old immunological assays no longer in use. assays with a lot of interference and cross reactivity leading to measurement of higher values for cortisol than what we measure on the highly specific lcms/ms ( liquid chromatography mass spectrometry methode) that we are using for cortisol today. so, there is a need for new cut off values for a normal response to such tests. the purpose of this study is to produce such new cutoff values by performing the test in 120 healthy controls. we also want to perform the test in patient groups normally going trough this tests according to the same protocol as the control persons, to evaluate the new cutoffs in different patient groups.

120 healthy controls will perform an intravenous synacthen test in our out patient clinic. we register anthropometric data, and take basal blood screening to assure they are healthy. we take basal blood and saliva samples right before start of the test ( called 0-samples). then they get intravenous synacthen, and we take new samples at 30 minutes and 60 minutes. they are observed during the procedure. we will then calculate a new cut off value for cortisol after the test, based on the 2.5 percentile for cortisol in this population. we will also calculate the same for 17-oh-progesterone, a parameter we also look at after synacthen test in som patient groups ( patients with hirsutism, who are suspicious of having an enzyme defect in the cortisol synthesis cascade). the saliva samples will also be analyzed for cortisol and 17-oh-progesterone, to evaluate if it is possible to use saliva instead of blood samples in synacthen tests in the future. the advantage of using saliva samples is that they can be used also in patients with elevated amount of cortisol binding globulin (cbg), because it measure the free hormone that is biological active ( not both the free and the protein bound, as we measure in serum samples). this is important in patients on estrogens , and in pregnant women, that have large amount of cbg.

Eligibility criteria:
inclusion criteria: * healthy individuals not using any corticosteroids . * patients with clinical suspicion of primary or secondary adrenal insufficiency. -patient suspicious of having an enzyme defect ( 21 hydroxylase deficiency) giving hirsutism. exclusion criteria: -use of corticosteroids.
genistein and endometrial hyperplasia

Conditions: Endometrial Hyperplasia

Summary: the aim of this study is to verify the anti-estrogenic activity of genistein, on the "non atypical endometrial hyperplasia", in premenopausal women.

although isoflavones alone (example: genistein) have weak estrogenic effects on endometrial stromal and glandular cells, it was demonstrated, in several research efforts, that in the presence of e2 they act as antiestrogens. considered that endometrial hyperplasia is due to strong and extended estrogenic stimulation, not offset by a proportionate amount of progesterone, we suppose that genistein could be therapeutic in these cases inducing a decrease of the hyperplasia and a change from the proliferative to a secretory phase of the endometrium.

Eligibility criteria:
inclusion criteria: * premenopausal women * age \> = 44 years * dysfunctional uterine bleeding * no treatment with other hormonal drugs (estrogen, progesterone) * no local or general pathology negatively influenced by administration of genistein or progesterone * no intrauterine pathologies (polyps, myomas) * a "non atypical endometrial hyperplasia", confirmed by hysteroscopy with biopsy and histological examination exclusion criteria: * all the other conditions

Keywords: endometrial hyperplasia genistein isoflavones dysfunctional uterine bleeding
dapsone gel7.5%versus trichloroacetic acid 20% on acne vulgaris

Conditions: Acne Vulgaris

Summary: acne vulgaris, a chronic inﬂammatory skin disorder, is one of the most prevalent diseases that eﬀects more than 80% of the population worldwide . a variety of factors such as genetics, hormones, infections, as well as environmental factors have been identiﬁed as the causes of acne development . acne usually generates as a result of blockage in the pilosebaceous unit (including hair follicle, hair shaft, and sebaceous gland) due to the over-produced sebum by sebaceous gland, which further triggers the excessive proliferation of the bacterium propionibacterium acnes (p. acnes).

chemical peeling can target the pathogenic factors recognized in acne and treat present primary and secondary lesions, it also improves the pigmentary changes seen with acne, and hastes the time taken to repair skin to normal. trichloroacetic acid (tca), salicylic acid (sa), and azelaic acid (aa) have proved efficacy in the treatment of acne as a result of their exfoliative and keratolytic properties . the mechanism of tca peel in the treatment of acne vulgaris is due to its ability to diminish corneocyte cohesion and keratinocyte plugging, thus helping in comedolytic action. in addition, application of tca to the skin causes precipitation of proteins and coagulative necrosis of epidermal cells, leading to removal of damaged skin and its replacement by normal tissue. dapsone is a "4,40-diamino diphenyl sulfone" compound and an aniline derivative from synthetic sulphones.. sulphonamides were first used in humans as antimicrobial agents to treat streptococcal infections. dapsone derived from sulphonamides was first used in the treatment of leprosy in 1940 . subsequently, it was used in the treatment of bullous dermatoses, especially dermatitis herpetiformis, and in the treatment of non-infectious inflammatory dermatoses, especially neutrophilic dermatoses . today, dapsone treatment is among the treatment options for many dermatological diseases. dapsone carries both bacteriostatic and anti-inflammatory properties. its antimicrobial effect stems from its sulfonamide-like ability to inhibit the synthesis of dihydrofolic acid . additionally, dapsone has multiple anti-inflammatory properties. it inhibits the production of reactive oxygen species directly and reversibly inhibits the myeloperoxidase enzyme thus decreasing hypochlorous acid formation. further more topical dapsone has been used with different concentration in treating acne vulgaris: both dapsone gel 7.5% and dapsone gel 5%has been used and found to be safe and effective

Eligibility criteria:
inclusion criteria: * both males and females will be included. * patients older than 12 years of age. * patients with mild and moderate av. * patients had not received any topical or systemic treatment for av during the previous 2 weeks exclusion criteria: * severe acne. * patients under treatment with contraceptive pills or any kind of systemic or topic acne medication (isotretinoin, antibiotics, topical products). * history of hypertrophic/keloid scar formation. * pregnancy, breast feeding. * recurrent herpes infection.
a study of acequias contamination & association of infectious diseases in peru

Conditions: Water-Related Diseases

Summary: a major water supply utilized in the lambayeque region are acequias. acequias are irrigation canals that are utilized by the agriculture industry for the cultivation of consumables. utilization of contaminated water to irrigate consumables can lead to foodborne illnesses. contamination studies on the acequias in the lambayeque region have not been performed to date. the purpose of this study is to test contamination of acequias in 9 districts in lambayeque and determine if a difference in infection rates exists in districts with contaminated acequias vs. districts without contaminated acequias for the following diseases: h. pylori, adenovirus, rotavirus.


Eligibility criteria:
inclusion criteria: * currently reside in one of the following districts: eten, pomalca, pimentel, patapo, pucala, santa rosa, reque, monsefu and sana * 18 years of age or older * consent to participate exclusion criteria: * currently taking antiviral or antimicrobial medication
prevalence of dental anomalies in oral clefts patients

Conditions: Anomaly

Summary: to assess the prevalence of dental anomalies in the deciduous dentition in children with oral clefts and to investigate the associated risk factors.

oral clefts lip and/or palate are considered as the most common oro-facial defects in children with an unclear complex etiology. the international prevalence in newborns was estimated as 14 per 10,000 live births worldwide. around 70% of cases occur as a non-syndromic cleft lip and/or cleft palate (nscl/p)\], and the resting 30% are associated with mendelian disorders or teratogenic, chromosomal and sporadic conditions. non syndromic cleft lip and/or palate divided into cleft lip (cl), cleft lip and palate (cl/p) and cleft palate (cp) based on epidemiological features and embryologic timing. the exact etiology is not completely known, but attributed to a mixture of genetic and environmental factors. the usefulness of epidemiological knowledge is important in assessing the burden of oral clefts in order to plan public health resources. also, knowing the causes of oral clefts, which stimulates research on primary prevention and treatments to improve the quality of health and care. the incidence of dental defects in cleft patients can be used as clinical indicators for defining cleft sub-phenotypes, as well as providing numbers of instances. dental anomalies in children can lead to an increased risk of dental problems from esthetic to orthodontic problems. in egypt, there is lacking of information on the occurrence of dental defects in the deciduous dentition of children with oral clefts. also oral clefts are complicated epidemiological condition and further investigations are needed to know about the risk factors of this situation.

Eligibility criteria:
inclusion criteria: * children with oral cleft lip and/or palate with ages varying from 4 to 6 years. * children with primary dentition. * parents who accept to participate in the study. * compliant children. exclusion criteria: * healthy children and their guardians * syndromic oral clefts children

Keywords: dental anomalies
safety and efficacy of chloroquine and primaquine for vivax malaria in bhutan

Conditions: Vivax Malaria

Summary: this research is intended to study the efficacy of chloroquine (cq) and primaquine (pq) for plasmodium vivax (p.vivax) infection, and also to study the recurrence rate among patients with p.vivax malaria on standard doses of cq and pq. for this study, pq will be withheld for 28 days so as to study the efficacy of cq alone. this study will assess whether cq is still effective against p.vivax or whether there are resistant p.vivax strains in bhutan.

this study aims to assess the efficacy of chloroquine alone, withholding primaquine until day 28. parasitic clearance and recurrence rates will be recorded. patients whose blood stage of parasites are not cleared with the standard dose of chloroquine, or any recurrences before day 28, will be treated with second line treatment (act). the patients blood level of chloroquine (drug concentration) at the time of a recrudescent infection will de determined to assess whether that could be due to resistance, or due to low level of chloroquine. any relapses occurring after day 28 when not receiving primaquine, or after completion of primaquine dosage for a total of 14 days (from day 29 to 42), will be treated with repeat doses of the initial treatment. the recurrence rates will be recorded so as to develop the next phase of the study where the two different doses of primaquine (high dose vs. low dose) will be compared.

Eligibility criteria:
inclusion criteria: * \>12 months of age * infection with p.vivax parasitaemia monoinfection * presence of axillary temperature \>37.5 degrees or history of fever during the past 24 hours * ability to swallow oral medication * ability and willingness to comply with the study protocol for the duration of the study, including 12 months follow up * informed consent from the patient/parent/guardian in the case of children exclusion criteria: * presence of general danger signs in children aged under 5 years or signs of severe malaria according to the definitions of who * presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm); * history of haemolysis or severe anaemia * acute anaemia \<7 mg/dl * presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, hiv/aids); * regular medication, which may interfere with antimalarial pharmacokinetics * history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s) * a positive pregnancy test or lactating
melatonin and nighttime blood pressure in african americans-8 mg study

Conditions: Hypertension

Summary: this purpose of this study is to test the effect of oral melatonin supplementation (8 mg per night for 4 weeks) on nighttime blood pressure in african americans with a history of elevated nighttime blood pressure.

the main outcome of interest is the mean nighttime blood pressure. the investigator is also trying to see the mechanism of action of melatonin on blood pressure by analyzing data from sleep studies to see if melatonin lowers blood pressure by providing a better quality of sleep or is that independent of the quality of sleep. the investigator is also looking into the effect of melatonin on sympathetic nervous system by measuring urinary catecholamines. finally, the investigator is looking into changes in vascular biology markers (p-selectin and e-selectin) on melatonin.

Eligibility criteria:
inclusion criteria: * males or females ages 18 to 64 * prior history of elevated nighttime blood pressure (bp) ((systolic blood pressure (sbp) \>115 mmhg)) * taking no more than 2 antihypertensive medications * african-american race (self-defined by the participant) exclusion criteria: * secondary forms of hypertension * presence of other diseases requiring treatment with bp lowering medications * known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and transient ischemic attacks) * diabetes mellitus (type 1 or 2) * cancer/malignancy other than nonmelanoma skin cancer * primary renal disease * serum creatinine \> 1.5 mg/dl in men or \> 1.4mg/dl in women * severe anemia * liver enzymes \> 2.5 times upper limits of normal * hepatitis b, hepatitis c, or hiv positive as assessed by questionnaire * current treatment with or regular use of calcium channel blocking agents, cyclooxygenase-2 or cox2-inhibitors, oral contraceptives, estrogen, sildenafil, vardenafil, tadalafil, antidepressants, corticosteroids, or warfarin * current use of melatonin or any sleep aids containing melatonin. * regular consumption (1 or more times per week) of any of the following of vitamin methyl b12, st. johns wort, feverfew, black and white mustard seeds, wolf berry seed * severe sleep apnea * night work * women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.

Keywords: melatonin hypertension blood pressure cardiovascular sleep nighttime nocturnal catecholamines sympathetic nervous system endothelial function african american
effect of metabolic therapy in patients with chronic ischemic heart disease

Conditions: Coronary Artery Disease; Type II Diabetes Mellitus

Summary: patients with coronary artery disease have an abnormal cardiac metabolism. the hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

the present study will evaluate the effect of free fatty acid inhibition with trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type ii diabetes. patients will undergo ambulatory ecg monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. patients will repeat the ambulatory ecg monitoring at the end of the study

Eligibility criteria:
inclusion criteria: coronary artery disease type ii diabetes mellitus - exclusion criteria: unstable coronary artery syndromes impaired liver and kidney function -

Keywords: coronary artery disease diabetes mellitus